Russell Targ

EQS-News: Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Retrieved on: 
Wednesday, February 22, 2023

Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Key Points: 
  • Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
    The issuer is solely responsible for the content of this announcement.
  • With more than 3.7bn€ in assets under management, Andera Partners is quickly reaching its 2025 target of 4 to 5bn€ under management and announces a new target of 6 to 8bn€ by 2028.
  • Ahead of its business plan, Andera Partners will reach 4bn€ in assets under management in 2023, thus achieving its initial 2025 target two years ahead of schedule.
  • In announcing a new target of 6 to 8bn€ in assets under management by 2028, Andera Partners outlines its ambitions for the next five years.

EQS-News: Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector

Retrieved on: 
Monday, October 10, 2022

Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector

Key Points: 
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    PARIS, 10 OCTOBER 2022 Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.
  • The sixth generation of BioDiscovery funds is consolidating Andera Partners position as one of the leading players in life sciences venture capital in Europe.
  • Its teams manage over 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

DGAP-News: Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients

Retrieved on: 
Tuesday, February 22, 2022

TargED's lead product, Microlyse, is a first-in-class proprietary clot-busting compound which binds to a protein present in all forms of thrombosis.

Key Points: 
  • TargED's lead product, Microlyse, is a first-in-class proprietary clot-busting compound which binds to a protein present in all forms of thrombosis.
  • Microlyse is the first compound to achieve targeted enzyme delivery, using a single domain antibody (VhH), directly to blood clots.
  • Andera Partners' mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth.
  • TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.